Nafld Clinical Trials 2022

Browse 31 Nafld Medical Studies Across 108 Cities

2 Phase 3 Trial · 273 Nafld Clinics

Clinical TrialsNafld Clinical Trials 2022
Reviewed by Michael Gill, B. Sc.
Photo of Edmonton 1
Phase-Based Progress Estimates
1
Effectiveness
1
Safety

Dietary Interventionfor Nonalcoholic Steatohepatitis

Edmonton, Canada
< 65
All Sexes
Obesity has been increasing all over the world. This has lead to a significant increase of a liver disease in children called non-alcoholic fatty liver disease (NAFLD). NAFLD is a liver disease that ranges from excess fat being stored in the liver to an inflamed and fatty liver with fibrosis to cirrhosis. NAFLD is thought to be caused by changes in energy, fat and carbohydrate metabolism induced by diets high in in processed foods. Sugary (especially high fructose corn syrup or HFCS) and fatty foods in processed foods have been shown to produce more insulin resistance, a factor that is thought to cause a fatty liver. Currently the main treatment for NAFLD is weight loss. However, it unknown the best way to achieve this. The investigator has shown previously that adolescents with NAFLD eat a lot of fatty and sugary foods, and that when they decrease the amount of foods they eat that contain HFCS, experience some improvements in insulin resistance and liver dysfunction even when they don't lose weight. The plan is to compare and contrast how two different diets (high vs low HFCS containing diets) may affect how much fat gets deposited in the liver and whether or not a lower diet in HFCS can help decrease liver damage in adolescents with NAFLD.
Recruiting
Has No Placebo
Photo of university of alabama at birmingham 1
Phase-Based Progress Estimates
1
Effectiveness
1
Safety

Moderately Carbohydrate-restricted Dietfor Obesity

Birmingham, AL
< 18
All Sexes
This will be a 6-month randomized clinical trial with two arms: moderately carbohydrate-restricted diet and a fat-restricted control diet. This 6-month study will have 2 phases: a 12-week controlled feeding phase and a 12-week "free living" phase. During the controlled feeding phase, all food will be provided to the families of the participants for the entirety of the 12 weeks. Participants (n=80) will have been diagnosed with NAFLD based on the presence of current evidence of active disease, which will be determined by the ongoing presence of hepatic steatosis estimated by diffusely echogenic liver via ultrasound suggestive of fatty liver and a serum alanine aminotransferase (ALT) level of 45 U/L or greater. All participants will be children and adolescents age 12-17 yrs.; will have an HbA1c <7.0; and will be overweight or obese (BMI >85th percentile). It is anticipated that most participants will be sedentary. The investigators will inquire as to routine physical activity at screening. All participants will be asked to maintain their usual level of physical activity throughout the study. Physical activity will be monitored via a smart watch provided to each participant at the beginning of the study, and participants will be queried weekly by the study dietitian regarding changes in physical activity. Participants who use oral contraceptives will be asked to maintain consistent use of these preparations throughout the study. Hormone use will be examined as a potential covariate in statistical analyses.
Recruiting
Has No Placebo
Photo of Iowa City 1
Phase-Based Progress Estimates
1
Effectiveness
1
Safety

Dietary Intervention With Very Low Calorie Dietfor (NAFLD)

Iowa City, IA
18+
All Sexes
This trial is testing whether a very low-calorie diet can help improve non-alcoholic fatty liver disease (NAFLD) by reducing liver steatosis (fatty infiltration) and fibrosis (scarring). If successful, this could establish the diet as a clinically effective option for treating NAFLD, particularly for patients who are ineligible or don't have access to bariatric surgery. Dietary intervention with a very low calorie diet is an effective treatment for non-alcoholic fatty liver disease (NAFLD). This treatment is free from any placebo effects. The dietary intervention has been previously approved by the FDA for a different condition.
Phase 1
Waitlist Available
Photo of montreal 1
Phase-Based Progress Estimates
1
Effectiveness
1
Safety

Omega 3for Fatty Liver, Non-alcoholic Fatty Liver Disease, NAFLD

Montreal, Canada
< 65
Male
Nonalcoholic hepatic steatosis (NASH) is defined as the amount greater than 5% of the total liver volume fat. Commonly known as NASH, it includes 4 stages histological ranging from the mere presence of fat to the existence of fibrosis and degeneration of hepatocytes, and finally a progression to cirrhosis, sometimes accompanied by complications of hepatocellular carcinoma. It is a common condition associated with a combination of disorders, namely obesity, insulin resistance and type 2 diabetes. The link with the metabolic syndrome (MetS) was mainly studied in the adult population and very little in the paediatric population, while 15 and 25% of obese children are affectés. The severity of histological disease appears to be associated with the degree of obesity in children and particularly in the MetS. in addition, epidemiological data indicate that the incidence of this disease is increasing in children and positioning as the first NASH liver disease in North America. the revelation of the factors associated with the occurrence of NASH is a first necessary step to understanding this disorder worrying for the future of children and adolescents. In addition, clarification of the mechanisms responsible for its development is essential if the investigators want to consider targeted and effective treatments to slow the rat race of NASH, which stands out as the supreme chronic liver accompanying the obesity and MetS. Finally, in view of growth and puberty of children, it would be extremely beneficial to find nutritional avenues that would avoid the side effects of chemical agents.
Phase 1 & 2
Waitlist Available
25 Nafld Clinical Trials Near Me
San Antonio, TX
Edmonton, Canada
Montreal, Canada
Birmingham, AL
More Trial Locations
An interactive map to display trial locations for Texas Liver Institute, Clinical Research Unit, University of Alberta, McGill University Health Center, University of Alabama at Birmingham, and 146 more locations.
Most Popular References for Nafld Clinical Trials
Frequency
Citation
11
Jensen, Michael D., Donna H. Ryan, Caroline M. Apovian, Jamy D. Ard, Anthony G. Comuzzie, Karen A. Donato, Frank B. Hu, et al.. 2014. “2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults”. Journal of the American College of Cardiology. Elsevier BV. doi:10.1016/j.jacc.2013.11.004.
7
Chalasani, Naga, Zobair Younossi, Joel E. Lavine, Michael Charlton, Kenneth Cusi, Mary Rinella, Stephen A. Harrison, Elizabeth M. Brunt, and Arun J. Sanyal. 2017. “The Diagnosis and Management of Nonalcoholic Fatty Liver Disease: Practice Guidance from the American Association for the Study of Liver Diseases”. Hepatology. Wiley. doi:10.1002/hep.29367.
6
Mouzaki M, Comelli EM, Arendt BM, Bonengel J, Fung SK, Fischer SE, McGilvray ID, Allard JP. Intestinal microbiota in patients with nonalcoholic fatty liver disease. Hepatology. 2013 Jul;58(1):120-7. doi: 10.1002/hep.26319. Epub 2013 May 14.
4
Ley RE, Peterson DA, Gordon JI. Ecological and evolutionary forces shaping microbial diversity in the human intestine. Cell. 2006 Feb 24;124(4):837-48. Review.
4
Ley RE, Bäckhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JI. Obesity alters gut microbial ecology. Proc Natl Acad Sci U S A. 2005 Aug 2;102(31):11070-5. Epub 2005 Jul 20.
4
Yoshino, Jun, Bruce W. Patterson, and Samuel Klein. 2019. “Adipose Tissue ctgf Expression Is Associated with Adiposity and Insulin Resistance in Humans”. Obesity. Wiley. doi:10.1002/oby.22463.
3
Wong, Robert J., Maria Aguilar, Ramsey Cheung, Ryan B. Perumpail, Stephen A. Harrison, Zobair M. Younossi, and Aijaz Ahmed. 2015. “Nonalcoholic Steatohepatitis Is the Second Leading Etiology of Liver Disease Among Adults Awaiting Liver Transplantation in the United States”. Gastroenterology. Elsevier BV. doi:10.1053/j.gastro.2014.11.039.
3
Ard, Jamy D., Kristina H. Lewis, Amy Rothberg, Anthony Auriemma, Sally L. Coburn, Sarah S. Cohen, Judy Loper, Laura Matarese, Walter J. Pories, and Seletha Periman. 2018. “Effectiveness of a Total Meal Replacement Program (OPTIFAST Program) on Weight Loss: Results from the OPTIWIN Study”. Obesity. Wiley. doi:10.1002/oby.22303.
3
Bajaj, Jasmohan S., Naga S. Betrapally, Phillip B. Hylemon, Douglas M. Heuman, Kalyani Daita, Melanie B. White, Ariel Unser, et al.. 2015. “Salivary Microbiota Reflects Changes in Gut Microbiota in Cirrhosis with Hepatic Encephalopathy”. Hepatology. Wiley. doi:10.1002/hep.27819.
3
Henao-Mejia, Jorge, Eran Elinav, Chengcheng Jin, Liming Hao, Wajahat Z. Mehal, Till Strowig, Christoph A. Thaiss, et al.. 2012. “Inflammasome-mediated Dysbiosis Regulates Progression of NAFLD and Obesity”. Nature. Springer Science and Business Media LLC. doi:10.1038/nature10809.
Top Hospitals for Nafld Clinical Trials
Location
Active Nafld Clinical Trials
All Time Trials for Nafld
First Recorded Nafld Trial
Trials
Catalina Research Institute, Montclair, California
4
11
2016
ALT-801 for Nonalcoholic Steatohepatitis
, Resmetirom for Liver Diseases
, Resmetirom for Nonalcoholic Steatohepatitis ... View More
South Texas Research Institute, Edinburg, Texas
4
13
2019
ALT-801 for Nonalcoholic Steatohepatitis
, Resmetirom for Liver Diseases
, Resmetirom for Nonalcoholic Steatohepatitis ... View More
Arkansas Gastroenterology, North Little Rock, Arkansas
3
11
2015
Resmetirom for Liver Diseases
, DHA EE (1.89 g) and Vitamin E (1000 mg) for Fatty Liver
, Resmetirom for Nonalcoholic Steatohepatitis
Duke University Medical Center, Durham, North Carolina
3
27
2005
Resmetirom for Liver Diseases
, Lisinopril for Carcinoma, Hepatocellular
, Resmetirom for Nonalcoholic Steatohepatitis
Florida Research Institute, Lakewood Ranch, Florida
3
18
2016
Resmetirom for Liver Diseases
, DHA EE (1.89 g) and Vitamin E (1000 mg) for Fatty Liver
, Resmetirom for Nonalcoholic Steatohepatitis
Top Treatments for Nafld Clinical Trials
Treatment Name
Active Nafld Clinical Trials
All Time Trials for Nafld
First Recorded Nafld Trial
Trials
ALT-801
2
4
2020
ALT-801 for Nonalcoholic Steatohepatitis
, ALT-801 for Fatty Liver, Non-alcoholic Fatty Liver Disease, NAFLD
Resmetirom
2
2
2019
Resmetirom for Liver Diseases
, Resmetirom for Nonalcoholic Steatohepatitis
Semaglutide
2
7
2016
Semaglutide for HIV Infections
, Semaglutide for Fatty Liver, Non-alcoholic Fatty Liver Disease, NAFLD
Intervention/ Drug
1
1
2022
Intervention/ Drug for Nonalcoholic Steatohepatitis
Dietary intervention
1
2
2015
Dietary intervention for Nonalcoholic Steatohepatitis
Top Cities for Nafld Clinical Trials
City
Active Nafld Clinical Trials
Top Active Site for Nafld Clinical Trials
Trial List
San Antonio, Texas
18
Texas Liver Institute
Intervention/ Drug for Nonalcoholic Steatohepatitis
, ALT-801 for Nonalcoholic Steatohepatitis
, ALT-801 for Nonalcoholic Steatohepatitis ... View More
Chandler, Arizona
9
Arizona Liver Health - Chandler
Resmetirom for Liver Diseases
, Resmetirom for Liver Diseases
, AMG 609 for Nonalcoholic Steatohepatitis ... View More
Tucson, Arizona
8
Adobe Gastroenterology
ALT-801 for Nonalcoholic Steatohepatitis
, Resmetirom for Liver Diseases
, Resmetirom for Liver Diseases ... View More
Richmond, Virginia
8
National Clinical Research - Richmond
Resmetirom for Liver Diseases
, Resmetirom for Liver Diseases
, Resmetirom for Liver Diseases ... View More
Austin, Texas
7
Accelemed Research Institute
ALT-801 for Nonalcoholic Steatohepatitis
, ALT-801 for Nonalcoholic Steatohepatitis
, Resmetirom for Liver Diseases ... View More
Which phases are most popular for nafld clinical trials?
Phase
Active Nafld Clinical Trials
Number of Unique Treatments
Number of Active Locations
Trial List
Phase 1
6
5
29
Intervention/ Drug for Nonalcoholic Steatohepatitis
, ALT-801 for Nonalcoholic Steatohepatitis
, Dietary intervention with very low calorie diet for (NAFLD) ... View More
Phase 1 & 2
2
2
0
omega 3 for Fatty Liver, Non-alcoholic Fatty Liver Disease, NAFLD
, Dose 3 for Liver Diseases
Phase 2
7
6
46
Efinopegdutide 20 mg/mL for Nonalcoholic Steatohepatitis
, Lisinopril for Carcinoma, Hepatocellular
, Semaglutide for HIV Infections ... View More
Phase 3
2
1
135
Resmetirom for Liver Diseases
, Resmetirom for Nonalcoholic Steatohepatitis
N/A
14
14
7
Dietary intervention for Nonalcoholic Steatohepatitis
, HIV without NAFLD for Steatohepatitis
, Moderately carbohydrate-restricted diet for Obesity ... View More
How many nafld clinical trials are open to youth and / or seniors?
Age Group
Active Nafld Clinical Trials
Trial List
< 18
2
Moderately carbohydrate-restricted diet for Obesity
, LFSD for Liver Diseases
18+
22
Intervention/ Drug for Nonalcoholic Steatohepatitis
, HIV without NAFLD for Steatohepatitis
, ALT-801 for Nonalcoholic Steatohepatitis ... View More
18 - 65
2
NAFLD-specific weight loss intervention for Nonalcoholic Steatohepatitis
, Saroglitazar Magnesium 4 mg Tablet for Fatty Liver
< 65
5
Dietary intervention for Nonalcoholic Steatohepatitis
, Probiotic group for Fatty Liver, Non-alcoholic Fatty Liver Disease, NAFLD
, MRI for Weight Loss ... View More
Most Recent Nafld Clinical Trials
Clinical Trial
Began Recruiting Date
Phase
Intervention/ Drug for Nonalcoholic Steatohepatitis
8/12/2022
Phase 1
Dietary intervention with very low calorie diet for (NAFLD)
7/1/2022
Phase 1
Moderately carbohydrate-restricted diet for Obesity
5/1/2022
N/A
Intervention- BT-NCBT-00x for Nonalcoholic Fatty Liver
4/10/2022
N/A
LFSD for Liver Diseases
4/6/2022
N/A
Phase 3 Nafld Clinical Trials
Clinical Trial
Began Recruiting Date
Phase
Resmetirom for Liver Diseases
7/9/2021
Phase 3
Resmetirom for Nonalcoholic Steatohepatitis
12/16/2019
Phase 3
Pediatric Nafld Clinical Trials
Clinical Trial
Began Recruiting Date
Phase
Moderately carbohydrate-restricted diet for Obesity
5/1/2022
N/A
LFSD for Liver Diseases
4/6/2022
N/A
Probiotic group for Fatty Liver, Non-alcoholic Fatty Liver Disease, NAFLD
9/7/2020
N/A
Modified Time-restricted Feeding for Fatty Liver, Non-alcoholic Fatty Liver Disease, NAFLD
4/1/2019
N/A
Dietary intervention for Nonalcoholic Steatohepatitis
4/30/2015
N/A
Senior Friendly Nafld Clinical Trials
Clinical Trial
Began Recruiting Date
Phase
Intervention/ Drug for Nonalcoholic Steatohepatitis
8/12/2022
Phase 1
Dietary intervention with very low calorie diet for (NAFLD)
7/1/2022
Phase 1
Intervention- BT-NCBT-00x for Nonalcoholic Fatty Liver
4/10/2022
N/A
ALT-801 for Fatty Liver, Non-alcoholic Fatty Liver Disease, NAFLD
3/9/2022
Phase 1
Time-Restricted, Intermittent Fasting for Fasting, Intermittent
2/1/2022
N/A
Recently Completed Studies with FDA Approved Treatments for Nafld
Treatment
Year
Mechanism of Action
Sponsor
Active Nafld Clinical Trials
BIO89-100
2021
89bio, Inc.
0
ORMD-0801 (Insulin) capsule 8 mg BD
2020
Insulin human
Oramed, Ltd.
0
PF-06865571
2020
Pfizer
0

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 13th, 2021

Last Reviewed: September 11th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

Relevant Clinical Trials

Uti Clinical Trials 2022
Varicose Veins Clinical Trials 2022
Vestibular Migraine Clinical Trials 2022
Vitamin D Deficiency Clinical Trials 2022
Von Willebrand Disease Clinical Trials 2022
Granulomatosis With Polyangiitis Clinical Trials 2022
Inflammatory Bowel Disease Clinical Trials 2022
Weight Gain Clinical Trials 2022
Acute Myeloid Leukemia Clinical Trials 2022
Acute Myelogenous Leukemia Clinical Trials 2022
Rett Syndrome Clinical Trials 2022
Hiv Infection Clinical Trials 2022
Choroideremia Clinical Trials 2022
Urinary Retention Clinical Trials 2022
Malignant Pleural Effusion Clinical Trials 2022
Spina Bifida Clinical Trials 2022
Missing Teeth Clinical Trials 2022
T-Cell Lymphoma Clinical Trials 2022
Diffuse Large B Cell Lymphoma Clinical Trials 2022
Cutaneous T Cell Lymphoma Clinical Trials 2022

Top Oncology Trials

Cancer Clinical Trials 2022
Pancreas Cancer Clinical Trials 2022
Prostate Cancer Clinical Trials 2022
Breast Cancer Clinical Trials 2022
Oncology Clinical Trials 2022
Pancreatic Cancer Clinical Trials 2022
Colon Cancer Clinical Trials 2022
Lung Cancer Clinical Trials 2022
Melanoma Clinical Trials 2022
Multiple Myeloma Clinical Trials 2022
Ovarian Cancer Clinical Trials 2022
Triple Negative Breast Cancer Clinical Trials 2022
Esophageal Cancer Clinical Trials 2022
CLL Clinical Trials 2022
Small Cell Lung Cancer Clinical Trials 2022
Leukemia Clinical Trials 2022
Mesothelioma Clinical Trials 2022
AML Clinical Trials 2022
Bladder Cancer Clinical Trials 2022
Brain Cancer Clinical Trials 2022

Popular Clinical Trials

COVID Clinical Trials 2022
Depression Clinical Trials 2022
ALS Clinical Trials 2022
Marijuana Clinical Trials 2022
Type 1 Diabetes Clinical Trials 2022
IVF Clinical Trials 2022
PTSD Clinical Trials 2022
Tinnitus Clinical Trials 2022
Diabetes Clinical Trials 2022
Coronavirus Clinical Trials 2022
Lupus Clinical Trials 2022
Psilocybin Clinical Trials 2022
Rheumatoid Arthritis Clinical Trials 2022
Multiple Sclerosis Clinical Trials 2022
Obesity Clinical Trials 2022
Psoriasis Clinical Trials 2022
Alzheimer's Disease Clinical Trials 2022
Asthma Clinical Trials 2022
Lyme Disease Clinical Trials 2022
Osteoarthritis Clinical Trials 2022
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top